source
- Kardigan extends biotech’s streak of big IPOs with $400M haulIncluding the heart drug developer’s offering, four biotechs in 2026 have raised at least $400 million in IPO proceeds — the most in a single year since 2021, according to BioPharma Dive data.BioPharma Dive · 2mo ago↗ source
- UniQure to file gene therapy for approval, reflecting major shifts at FDAThe decision marks another regulatory U-turn following the exits of Marty Makary and Vinay Prasad, suggesting to some analysts that current FDA leadership may be more flexible in certain cases.BioPharma Dive · 2mo ago↗ source
- Jazz zeroes in on next-gen T cell engagers with AbCellera dealThe potentially $4 billion collaboration is the latest example of drugmakers working to broaden the use of T cell engagers, which, so far, have had limited success outside of certain blood cancers.